Global Information
회사소개 | 문의 | 비교리스트

지루성 피부염 : 역학에 근거한 현재(2020년) 시장 규모와 예측(-2030년), 경쟁사 신약 가격 전략, 거래 가치 평가 r-NPV, 파이프라인약 분석(2021년 하반기)

Seborrheic Dermatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021

리서치사 GervanoRA Data Services LLP
발행일 2021년 11월 상품 코드 1035550
페이지 정보 영문 210 Pages
가격
US $ 7,000 ₩ 8,417,000 PDF (General License)


지루성 피부염 : 역학에 근거한 현재(2020년) 시장 규모와 예측(-2030년), 경쟁사 신약 가격 전략, 거래 가치 평가 r-NPV, 파이프라인약 분석(2021년 하반기) Seborrheic Dermatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021
발행일 : 2021년 11월 페이지 정보 : 영문 210 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

지루성 피부염(Seborrheic Dermatitis) 시장에 대해 조사했으며, 지루성 피부염 영역에서의 시장 역학, 현재 진행중인 연구개발 분석, 부문별(개발 단계·투여 경로·지역·작용기전·약제 클래스·분자 유형별·표적 분자·기업 유형) 파이프라인 분석 및 평가, 세계 전체 및 지역(미국, 유럽 9개국별(폴란드, 러시아, 스위스, 스웨덴, 이탈리아, 독일, 오스트리아, 프랑스, 영국), 중국) 상세한 시장 동향, 역학 연구, 시장 규모와 예측, 신규 참여 기업의 시장 점유율 예측, KOL(Key Opinion Leader) 인사이트를 활용한 신규 참여 기업의 가격 전략, 미충족 요구와 기회, 거래 동향 등에 대한 정보를 제공합니다.

목차

제1장 서론

제2장 개요

제3장 지루성 피부염 개요와 역학 조사

제4장 지루성 피부염 시장 규모와 예측(2020-2030년)

제5장 파이프라인 인사이트와 벤치마크 현황 비교

제6장 지루성 피부염 거래 동향

제7장 지루성 피부염 파이프라인 의약품 특허 비교 분석

제8장 리스크 조정 순현재가치(R-NPV) 분석

제9장 경쟁 기회 평가

제10장 시장 역학

제11장 경쟁사의 신약 가격 전략

LSH 21.11.22

LIST OF TABLES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: WORLDWIDE EPIDEMIOLOGY INSIGHTS OF SEBORRHEIC DERMATITIS
  • TABLE 03: GLOBAL SEBORRHEIC DERMATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 04: US SEBORRHEIC DERMATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 05: UK SEBORRHEIC DERMATITIS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 06: LIST OF NEW ENTRANTS CONSIDERED FOR MARKET ESTIMATIONS
  • TABLE 07: SEBORRHEIC DERMATITIS GLOBAL CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 08: SEBORRHEIC DERMATITIS US CURRENT MARKET (2020), FORECAST (2021-2030)
  • TABLE 09: COMPARISON OF SEBORRHEIC DERMATITIS MARKET VALUES GLOBAL VERSUS US (2020-2030)(M$)
  • TABLE 10: PIPELINE ASSETS IN SEBORRHEIC DERMATITIS DRUG PIPELINE
  • TABLE 11: SPECIAL REGULATORY ALLOWANCES GRANTED FOR SEBORRHEIC DERMATITIS PIPELINE DRUGS
  • TABLE 12: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • TABLE 13: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY DRUG CLASS
  • TABLE 14: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • TABLE 15: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • TABLE 16: MAJOR MERGERS AND ACQUISITIONS IN SEBORRHEIC DERMATITIS THERAPEUTIC AREA
  • TABLE 17: MAJOR COLLABORATION AGREEMENTS IN SEBORRHEIC DERMATITIS THERAPEUTIC AREA
  • TABLE 18: MAJOR LICENSING AGREEMENTS IN SEBORRHEIC DERMATITIS THERAPEUTIC AREA
  • TABLE 19: MAJOR FINANCING AGREEMENTS IN SEBORRHEIC DERMATITIS THERAPEUTIC AREA
  • TABLE 20: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN SEBORRHEIC DERMATITIS THERAPEUTIC AREA
  • TABLE 21: COMPANIES LOOKING FOR CORPORATE PARTNERING, LICENSING, FUNDING OPPORTUNITIES
  • TABLE 22: ESTIMATED R&D INVESTMENTS OF NEW ENTRANTS

LIST OF FIGURES

(COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: SEBORRHEIC DERMATITIS FORECASTED PREVALENCE & INCIDENCE OF US, EUROPE AND CHINA, 2020 V/S 2030
  • FIGURE 02: GLOBAL SEBORRHEIC DERMATITIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 03: US SEBORRHEIC DERMATITIS POPULATION (2020) FORECAST (2021-2030)
  • FIGURE 04: GLOBAL SEBORRHEIC DERMATITIS MARKET CURRENT (2020) AND FORECAST (2021-2030)
  • FIGURE 05: US CURRENT (2020) SEBORRHEIC DERMATITIS MARKET VALUE COMPARED WITH GLOBAL MARKET (M$)
  • FIGURE 06: YEAR BY YEAR COMPARISON OF SEBORRHEIC DERMATITIS MARKET VALUES GLOBAL VS USA (2020 - 2030) (M$)
  • FIGURE 07: SEBORRHEIC DERMATITIS PIPELINE DRUGS ANALYTICS
  • FIGURE 08: SEBORRHEIC DERMATITIS PIPELINE DRUGS ANALYTICS BY HSD
  • FIGURE 09: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY ROA
  • FIGURE 10: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY DRUG CLASS
  • FIGURE 11: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY DRUG CLASS VERSUS HSD
  • FIGURE 12: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY MECHANISM OF ACTION
  • FIGURE 13: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 14: SEBORRHEIC DERMATITIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 15: SEBORRHEIC DERMATITIS DEALS ANALYTICS BY DEAL TYPE

GervanoRA's pipeline analysis and opportunity assessment report "Seborrheic Dermatitis - Epidemiology Based Current (2020) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal worth Assessments, r-NPV and Pipeline Drugs Analytics H2 2021" analysed and assessed Seborrheic Dermatitis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Seborrheic Dermatitis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Seborrheic Dermatitis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Seborrheic Dermatitis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Seborrheic Dermatitis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Seborrheic Dermatitis Market (2020) and the Forecasted Seborrheic Dermatitis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Seborrheic Dermatitis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Seborrheic Dermatitis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Seborrheic Dermatitis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: SEBORRHEIC DERMATITIS OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: SEBORRHEIC DERMATITIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: COMPARATIVE PIPELINE INSIGHTS AND BENCHMARKING SNAPSHOTS

CHAPTER 6: DEALS ACTIVITIES OF SEBORRHEIC DERMATITIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF SEBORRHEIC DERMATITIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

CHAPTER 10: MARKET DYNAMICS

CHAPTER 11: COMPETITOR NEW DRUGS PRICING STRATEGIES

Back to Top
전화 문의
F A Q